Strand Life Sciences, a Reliance Industries subsidiary, introduced the launch of its superior proteomics capabilities, marking a milestone in its large-scale multi-omics analysis in India and South Asia, it mentioned.
The potential enabled by the ‘OlinkTM Discover HT’ platform helps measure over 5,400 protein biomarkers from simply 2 μL of pattern — roughly one-twenty-fifth of a single drop of blood — permitting Strand to ship built-in proteomics, genomics, and scientific insights for superior analysis and drug discovery, it mentioned.
Each residing cell produces hundreds of proteins — the molecular machines that perform nearly each organic perform within the physique, from preventing an infection to regulating metabolism, the corporate mentioned.
And proteomics is the research of those proteins, and their function in well being and illness. “It tells us what is definitely being constructed and in what portions — making it one of the crucial direct home windows into the biology of illness,” the word mentioned.
Subsequent-generation proteomics platforms have enabled the simultaneous evaluation of hundreds of proteins from a single, small blood pattern. The result’s a richer, quicker, and much more actionable image of illness biology — one which helps extra exact therapy choice, and the invention of latest drug targets, it added.
Guiding therapy
Strand has accomplished a proteomics venture for a biopharma companion, involving sufferers with continual kidney illness, demonstrating the platform’s potential in translational analysis and scientific research, it mentioned.
For pharmaceutical and biotechnology corporations, this functionality cuts brief time, for instance – “analysis programmes that after required time intensive sequential investigation can now be compressed into built-in, large-scale research,” it mentioned. For clinicians and sufferers, the promise is equally important, Strand mentioned.
“Biomarkers recognized via proteomics can information therapy choices with higher confidence and open new frontiers in precision drugs.”
Dr Ramesh Hariharan, Chief Govt, Strand Life Sciences, mentioned: “With OlinkTM Discover HT, Strand is bringing one of many world’s most superior proteomics platforms to India and the area. By combining this with established strengths in genomics, bioinformatics, and scientific partnerships, Strand goals to ship end-to-end multi-omics programmes and allow quicker, extra impactful discovery.” By its scientific companions, the corporate allows research throughout therapeutic areas, together with oncology, nephrology, metabolic illnesses, and uncommon problems. Strand is participating with international educational, pharmaceutical, and biotechnology organisations searching for to conduct discovery, validation, and translational analysis programmes at scale, it mentioned.
Printed on Might 19, 2026
